Table 1 Clinical characteristics of the endocrine-treated patients
From: Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
Training | Validation | |||||||
|---|---|---|---|---|---|---|---|---|
HR | 95% CI | P -value | N | HR | 95% CI | P -value | N | |
Age (<55) | 1.791 | 0.44–7.32 | 0.417 | 576 | 0.856 | 0.52–1.40 | 0.535 | 1974 |
Nodal Status | ||||||||
0 vs. 1–3 | 1.372 | 0.81–2.33 | 0.240 | 567 | 1.323 | 0.98–1.78 | 0.066 | 1925 |
0 vs. 4–9 | 3.314 | 1.46–7.53 | 0.004 | 4.021 | 2.77–5.83 | 1.916 × 10−13 | ||
0 vs. 10+ | 4.973 | 1.75–14.10 | 0.003 | 6.562 | 4.17–10.34 | 4.907 × 10−16 | ||
Pathological Size (Categorical) | ||||||||
≤2 vs. (>2 cm & ≤5 cm) | 1.953 | 1.19–3.20 | 0.008 | 576 | 2.148 | 1.63–2.83 | 5.765 × 10−08 | 1972 |
≤2 vs. >5 | 3.096 | 0.94–10.17 | 0.063 | 2.755 | 1.75–4.33 | 1.117 × 10−5 | ||
Pathological Size (Continuous) | 1.163 | 1.06–1.27 | 0.001 | 560 | 1.311 | 1.21–1.42 | 9.401 × 10−12 | 1963 |
Grade | ||||||||
1 vs. 2 | 1.835 | 0.56–5.99 | 0.315 | 563 | 1.433 | 0.90–2.29 | 0.131 | 1869 |
1 vs. 3 | 3.341 | 1.02–10.93 | 0.046 | 2.606 | 1.64–4.15 | 5.452 × 10−5 | ||
HER2 | 2.31 | 1.33–4.02 | 0.003 | 564 | 1.835 | 1.32–2.55 | 2.745 × 10−4 | 1890 |
